Study updates top January retina coverage
News detailing the first patient dosed in a clinical trial for AXT107 led retina coverage in the beginning of January.
Read the rest of the top-performing retina articles below.
First patient dosed in AXT107 clinical trial for DME
The first patient has been dosed in a phase 1/2a clinical trial of AXT107 to evaluate the safety and bioactivity of the therapy in patients with diabetic macular edema. Read more.
Notal Vision initiates study investigating at-home OCT monitoring of AMD
Notal Vision has initiated a longitudinal study to evaluate the ability of patients with wet age-related macular degeneration to perform daily self-imaging of their eyes using the Notal Home OCT device. Read more.
Adverum completes enrollment in phase 2 DME trial
Adverum Biotechnologies has completed enrollment in the phase 2 INFINITY trial to evaluate a single injection of ADVM-022 for the treatment of diabetic macular edema. Read more.
Central foveal thickness transiently increases after anti-VEGF switch in DME
Patients treated for diabetic macular edema who were switched from aflibercept to ranibizumab experienced a transient increase in central foveal thickness. Read more.
Q&A: International Council of Ophthalmology supports WHO’s guide on DR screening
The International Council of Ophthalmology participated in the launch of a diabetic retinopathy screening guide developed by the WHO Regional Office for Europe. Read more.